Skip to main content

Table 1 FXIIa-serpin complexes and aCL antibodies in association with VD in SLE patients

From: Contact activation products are new potential biomarkers to evaluate the risk of thrombotic events in systemic lupus erythematosus

 

VD-, n (%)

VD+, n (%)

P-value a

OR (95% CI)

All

38 (55)

31 (45)

  

FXIIa-C1INH <0.01 nMb

14 (37)

24 (77)

P <0.0001

8.9 (2.8, 28.5)

FXIIa-AT >0.40 nMc

4 (11)

13 (42)

P = 0.0043

6.1 (1.7, 21.6)

Both low FXIIa-C1INH

1 (3)

12 (39)

P <0.0001

23.4 (2.8, 194)

and high FXIIa-AT

aCL antibodies

12 (32)

15 (48)

n.s.

2.0 (0.8, 5.4)

  1. SLE, systemic lupus erythematosus; VD, vascular disease; F, factor; C1INH, C1 inhibitor; AT, antithrombin; Acl, anti-cardiolipin; OR, odds ratio; n.s., not significant. aFisher's exact test; b0.01 nM = detection limit of the assay; c0.40 nM = 90% percentile of controls.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us